Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ganoderma Spores Modulate the Gut-Brain Axis
Sponsor: Ling Zhiqiang
Summary
This study aims to investigate whether Sporoderm-removed Ganoderma lucidum spore powder (RGLS) ameliorates depression in thyroid cancer patients through gut-brain axis modulation, and to elucidate the underlying microbial and metabolic mechanisms. This 3-month randomized, double-blind, placebo-controlled trial will enroll 300 postoperative papillary thyroid carcinoma patients with depressive symptoms (HAMD-24 ≥ 8). Participants will be randomly assigned(2 : 1) to receive RGLS (2 g/day) or matched placebo.
Official title: Targeting the Gut-Brain Axis With Ganoderma Lucidum Spores Ameliorates Depression in Thyroid Cancer Patients: a Randomized, Double-blind, Placebo-controlled Trial
Key Details
Gender
FEMALE
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2026-04-15
Completion Date
2026-08-31
Last Updated
2026-04-13
Healthy Volunteers
No
Conditions
Interventions
Sporoderm-removed Ganoderma lucidum spore powder (RGLS)
From the first day after enrollment, subjects take RGLS orally at 4g/day for 3 months.
Placebo
From the first day after enrollment, subjects take placebo orally at 4g/day for 3 months.